Table 1 Patient demographics and disease characteristics

From: Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial

Subject No.

Age

Cancer type

Grade

Stage

Histology & Molecular Subtypes

Treatment

CURATE001

74

Rectal

Moderately differentiated (grade 2)

IV

Adenocarcinoma, NRAS exon 3 mutation, KRAS wildtype, BRAF wildtype, HER2 negative, pMMR

XELIRI (Capecitabine + Irinotecan)

CURATE002

71

Sigmoid Colon

Moderately differentiated (grade 2)

IV

Adenocarcinoma, CEA secretor, pMMR, BRAF wildtype, KRAS exon 2 mutation

XELOX (Capecitabine + Oxaliplatin)

CURATE003

67

Rectal

Moderately differentiated (grade 2)

IV

Adenocarcinoma, BRAF wildtype, KRAS exon 3 mutation, pMMR, Her2 negative

XELOX (Capecitabine + Oxaliplatin)

CURATE004

48

Sigmoid Colon

Poorly Differentiated (grade 3)

IV

Adenocarcinoma, BRAF wildtype, KRAS exon 3 mutation, KRAS wildtype pMMR, Her2 negative

1 cycle single-agent Capecitabine, then 2 cycles XELIRI (Capecitabine + Oxaliplatin)

CURATE005

45

Sigmoid Colon

Moderately differentiated (grade 2)

IV

Adenocarcinoma, KRAS wildtype, BRAF Exon 15 mutation, PMMR

1 cycle XELOX - (Capecitabine + Oxaliplatin), then 3 cycles XELOX (Capecitabine + Oxaliplatin) + Bevacizumab

CURATE006

69

Colon

Moderately differentiated (grade 2)

IV

Adenocarcinoma, KRAS Exon 2 Mutation, BRAF wildtype, pMMR

XELOX (Capecitabine + Oxaliplatin)

CURATE007

52

Colon

Moderately differentiated (grade 2)

IV

Adenocarcinoma, KRAS Exon 2 Mutation, BRAF wildtype, pMMR

6 cycles XELIRI (Capecitabine + Irinotecan) + Bevacizumab, then 2 cycles single-agent Capecitabine

CURATE008

57

Sigmoid Colon

Moderately to poorly differentiated (grade 2-3)

IV

Adenocarcinoma, KRAS Exon 2 mutation, BRAF wildtype, HER2 negative, pMMR

XELIRI (Capecitabine + Irinotecan)

CURATE010

68

Rectosigmoid Colon

Poorly Differentiated (grade 3)

IV

Adenocarcinoma, NRAS wildtype, KRAS wildtype, BRAF wildtype, HER2 negative, pMMR

XELOX (Capecitabine + Oxaliplatin)

CURATE011

63

Rectosigmoid Colon

Not available

IV

Adenocarcinoma, KRAS Exon 2 mutation, BRAF wildtype, HER2 negative, pMMR

8 cycles XELOX (Capecitabine + Oxaliplatin), then 4 cycles single-agent Capecitabine

  1. NRAS neuroblastoma rat sarcoma viral oncogene homolog, KRAS Kirsten rat sarcoma viral oncogene homolog, BRAF V-Raf murine sarcoma viral oncogene homolog B, HER2 human epidermal growth factor receptor 2, pMMR proficient mismatch repair.
Back to article page